FY2026 EPS Estimates for Exelixis Cut by Leerink Partnrs

Exelixis, Inc. (NASDAQ:EXEL) – Investment analysts at Leerink Partnrs reduced their FY2026 EPS estimates for shares of Exelixis in a research report issued to clients and investors on Tuesday, October 21st. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will earn $2.35 per share for the year, down from their prior forecast of $2.75. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The business had revenue of $568.26 million for the quarter, compared to analysts’ expectations of $574.36 million. During the same period in the prior year, the company posted $0.84 EPS. The business’s revenue for the quarter was down 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS.

Several other equities research analysts have also commented on the stock. Citigroup reiterated a “market outperform” rating on shares of Exelixis in a research report on Tuesday. Wall Street Zen upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Barclays began coverage on shares of Exelixis in a research report on Wednesday, September 17th. They issued an “equal weight” rating and a $40.00 price objective on the stock. The Goldman Sachs Group began coverage on shares of Exelixis in a research report on Wednesday, September 17th. They issued a “buy” rating and a $47.00 price objective on the stock. Finally, Zacks Research lowered shares of Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $44.53.

Exelixis Stock Down 0.1%

Exelixis stock opened at $36.08 on Thursday. Exelixis has a 52 week low of $27.86 and a 52 week high of $49.62. The firm’s 50-day simple moving average is $38.68 and its 200 day simple moving average is $39.99. The firm has a market capitalization of $9.71 billion, a PE ratio of 17.35, a P/E/G ratio of 0.72 and a beta of 0.38.

Institutional Trading of Exelixis

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Robeco Institutional Asset Management B.V. increased its position in Exelixis by 7.6% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 980,245 shares of the biotechnology company’s stock worth $40,484,000 after purchasing an additional 69,396 shares in the last quarter. CWA Asset Management Group LLC increased its position in Exelixis by 11.7% during the 3rd quarter. CWA Asset Management Group LLC now owns 47,157 shares of the biotechnology company’s stock worth $1,948,000 after purchasing an additional 4,946 shares in the last quarter. Oregon Pacific Wealth Management LLC acquired a new stake in Exelixis during the 3rd quarter worth approximately $226,000. TriaGen Wealth Management LLC acquired a new stake in Exelixis during the 3rd quarter worth approximately $2,024,000. Finally, Commonwealth Equity Services LLC increased its position in Exelixis by 43.3% during the 3rd quarter. Commonwealth Equity Services LLC now owns 381,659 shares of the biotechnology company’s stock worth $15,763,000 after purchasing an additional 115,395 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.